NCT05962073

Brief Summary

Hypoxemia during endotracheal intubation is one of this procedure's most frequent and severe complications, which can lead to cardiac arrest and other adverse outcomes. Although various studies have been conducted to ensure the safety of endotracheal intubation, most of them have focused on the physiological changes during the procedure in surgical settings, where general anesthesia is administered to healthy subjects. However, the physiological characteristics of critically ill patients who require endotracheal intubation in the intensive care unit (ICU) may differ from those of healthy subjects. When comparing the oxygen saturation-dissociation curve of healthy subjects and critically ill patients, the latter show a steeper decline in oxygen saturation (SpO2) below 90% when hypoxemia occurs. Clinically, it is difficult to maintain or recover oxygen saturation when it drops. Therefore, preoxygenation is also essential for critically ill patients with a relatively small lung reservoir, as it can help maintain higher and longer oxygen saturation during endotracheal intubation. For this reason, apneic oxygenation was proposed in the 1950s as a method of oxygen delivery during general anesthesia for surgery, and clinical randomized controlled trials (RCTs) applying it to critically ill patients in the ICU have been conducted since 20 years ago. In an observational study by Macamn et al., the adjusted odds ratio (OR) of a bag valve mask was 1, while that of a high-flow nasal cannula (HFNC) was 5.75 and that of non-invasive ventilation (NIV) was 0.10 when different preoxygenation methods were used. n FLORARI 2, a large-scale clinical RCT comparing NIV and HFNC with or without apneic oxygenation, NIV was significantly more effective than HFNC in reducing severe hypoxemia. Based on these previous studies, the investigators can infer that supplying oxygen during laryngoscopy is not very effective in preventing hypoxemia in critically ill patients. However, there is no guideline on which device to choose for preoxygenation in the ICU, and NIV or HFNC are selected according to the operator's preference. This is because few studies have examined the physiological effects of these devices on patients. Therefore, in this study, the investigators aim to compare the clinical outcomes and adverse events of NIV and HFNC as preoxygenation methods for endotracheal intubation in critically ill patients with acute respiratory failure and to evaluate their physiological effects using electrical impedance tomography.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Aug 2023

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 3, 2023

Completed
24 days until next milestone

First Posted

Study publicly available on registry

July 27, 2023

Completed
5 days until next milestone

Study Start

First participant enrolled

August 1, 2023

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2024

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2024

Completed
Last Updated

April 17, 2024

Status Verified

April 1, 2024

Enrollment Period

7 months

First QC Date

July 3, 2023

Last Update Submit

April 15, 2024

Conditions

Keywords

electrical impedence tomographypreoxygenationintubation

Outcome Measures

Primary Outcomes (1)

  • Lowest SpO2

    Minimum SpO2 value during endotracheal intubation

    at day1(before, during and after preoxygenation and at 5 minutes and at 30 minutes after intubation)

Secondary Outcomes (6)

  • EIT measurement

    at day1(before, during and after preoxygenation and at 5 minutes and at 30 minutes after intubation)

  • EIT measurement

    at day1(before, during and after preoxygenation and at 5 minutes and at 30 minutes after intubation)

  • EIT measurement

    at day1(before, during and after preoxygenation and at 5 minutes and at 30 minutes after intubation)

  • EIT measurement

    at day1(before, during and after preoxygenation and at 5 minutes and at 30 minutes after intubation)

  • EIT measurement

    at day1(before, during and after preoxygenation and at 5 minutes and at 30 minutes after intubation)

  • +1 more secondary outcomes

Study Arms (2)

NIV

NO INTERVENTION

Non-invasive ventilation application for preoxygenation

HFNC

ACTIVE COMPARATOR

High flow oxygen therapy application for preoxygenation

Device: HFNC

Interventions

HFNCDEVICE

High-flow oxygen therapy before intubation for preoxygenation

HFNC

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients aged 18 or older
  • Acute respiratory failure is defined as follows: Tachypnea over 30 breaths/minute / Symptoms or signs of respiratory failure / PaO2/FiO2 less than 300
  • When there is an indication for endotracheal intubation for mechanical ventilation
  • When sufficient information and a consent form for the study are obtained from the patient or the patient's guardian

You may not qualify if:

  • Coma with Glasgow score \< 8
  • Endotracheal intubation during CPR
  • Contraindications for NIV: poor patient cooperation, recurrent vomiting, GI bleeding, severe craniofacial injury, upper airway obstruction, etc.
  • Contraindications for RSI: complete upper airway obstruction, severe trauma obscuring cervical structures, etc.
  • Implanted electronic medical devices (defibrillator, pacemaker or spinal cord stimulator)
  • Skin damage or inadequate electrode contact due to wound dressing at the electrode site
  • BMI \> 50
  • Polydipsia
  • Unmeasurable SpO2
  • Pregnancy or lactation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Samsung Medical Center

Seoul, Gangnam, 06351, South Korea

Location

MeSH Terms

Conditions

Respiratory Insufficiency

Condition Hierarchy (Ancestors)

Respiration DisordersRespiratory Tract Diseases
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Hypoxemic respiratory failure who required endotracheal intubation
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical assistant professor

Study Record Dates

First Submitted

July 3, 2023

First Posted

July 27, 2023

Study Start

August 1, 2023

Primary Completion

February 28, 2024

Study Completion

July 30, 2024

Last Updated

April 17, 2024

Record last verified: 2024-04

Locations